Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial

Complementary Therapies in Medicine

Volumn 33, Issue , 2017, Pages 1-5

  Panahi, Yunes ^a   Khalili, Nahid ^b   Sahebi, Ebrahim ^c   Namazi, Soha ^c   Reiner, Željko ^d   Majeed, Muhammed ^e   Sahbekar, Amirhossein ^f  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KBC Zagreb   (Croatia)

^e SABINSA CORPORATION   (United States)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Cholesterol; Curcumin; Diabetes; Dyslipidemia; Lipoprotein(a)

Indexed keywords

CHOLESTEROL; CURCUMINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; PIPERINE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ALKALOID; AMIDE; CURCUMIN; PIPERIDINE DERIVATIVE; PLANT EXTRACT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; BLOOD; CHEMISTRY; COMPLICATION; CURCUMA; DIETARY SUPPLEMENT; DYSLIPIDEMIAS; MIDDLE AGED; PHYTOTHERAPY;

ADULT; ALKALOIDS; BENZODIOXOLES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CURCUMA; CURCUMIN; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PHYTOTHERAPY; PIPERIDINES; PLANT EXTRACTS; POLYUNSATURATED ALKAMIDES; TRIGLYCERIDES;

EID: 85019977787     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2017.05.006     Document Type: Article

References (52)

1. Anand, P., Thomas, S.G., Kunnumakkara, A.B., et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76:11 (2008), 1590–1611.
2. Karimian, M.S., Pirro, M., Johnston, T.P., Majeed, M., Sahebkar, A., Curcumin and endothelial function: evidence and mechanisms of protective effects. Curr Pharm Des, 2017.
3. Zabihi, N.A., Pirro, M., Johnston, T.P., Sahebkar, A., Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des, 2016.
4. Mirzaei, H., Naseri, G., Rezaee, R., et al. Curcumin: a new candidate for melanoma therapy?. Int J Cancer 139:8 (2016), 1683–1695.
5. Sahebkar, A., Henrotin, Y., Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-Analysis of randomized controlled trials. Pain Med 17:6 (2016), 1192–1202.
6. Panahi, Y., Badeli, R., Karami, G.R., Sahebkar, A., Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res. PTR 29:1 (2015), 17–21.
7. Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., Jirawatnotai, S., Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35:11 (2012), 2121–2127.
8. Na, L.X., Li, Y., Pan, H.Z., et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 57:9 (2013), 1569–1577.
9. Panahi, Y., Sahebkar, A., Amiri, M., et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 108:7 (2012), 1272–1279.
10. Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Majeed, M., Sahebkar, A., Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin. Nutr. 34:6 (2015), 1101–1108.
11. Panahi, Y., Alishiri, G.H., Parvin, S., Sahebkar, A., Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J. Dietary Suppl. 13:2 (2016), 209–220.
12. Panahi, Y., Ghanei, M., Hajhashemi, A., Sahebkar, A., Effects of curcuminoids-Piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J. Dietary Suppl. 13:1 (2016), 93–105.
13. Sahebkar, A., Mohammadi, A., Atabati, A., et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother. Res. PTR 27:12 (2013), 1883–1888.
14. Panahi, Y., Sahebkar, A., Parvin, S., Saadat, A., A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49:Pt 6 (2012), 580–588.
15. Ghandadi, M., Sahebkar, A., Curcumin: an effective inhibitor of interleukin-6. Curr Pharm Des, 2016.
16. Karimian, M.S., Pirro, M., Majeed, M., Sahebkar, A., Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev 33 (2017), 55–63.
17. Derosa, G., Maffioli, P., Simental-Mendia, L.E., Bo, S., Sahebkar, A., Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 111 (2016), 394–404.
18. Sahebkar, A., Cicero, A.F., Simental-Mendia, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107 (2016), 234–242.
19. Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. PTR 28:5 (2014), 633–642.
20. Ganjali, S., Sahebkar, A., Mahdipour, E., et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. Sci World J, 2014, 2014, 898361.
21. Sahebkar, A., Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. BioFactors 39:2 (2013), 197–208.
22. Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E., Sahebkar, A., Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol 68:3 (2016), 223–229.
23. Panahi, Y., Ahmadi, Y., Teymouri, M., Johnston, T.P., Sahebkar, A., Curcumin as a potential candidate for treating hyperlipidemia: a review of cellular and metabolic mechanisms. J Cell Physiol, 2016.
24. Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 11(2), 2014, 123.
25. Ganjali, S., Blesso, C.N., Banach, M., Pirro, M., Majeed, M., Sahebkar, A., Effects of curcumin on HDL functionality. Pharmacol Res 119 (2017), 208–218.
26. DiSilvestro, R.A., Joseph, E., Zhao, S., Bomser, J., Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J, 11, 2012, 79.
27. Mohammadi, A., Sahebkar, A., Iranshahi, M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res PTR 27:3 (2013), 374–379.
28. Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Therap Med 22:5 (2014), 851–857.
29. Alwi, I., Santoso, T., Suyono, S., et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indonesiana 40:4 (2008), 201–210.
30. Rahmani, S., Asgary, S., Askari, G., et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res PTR 30:9 (2016), 1540–1548.
31. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P.S., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:4 (1998), 353–356.
32. Sahebkar, A., A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr 33:3 (2014), 406–414.
33. European Association for Cardiovascular P, Rehabilitation, Reiner, Z., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:14 (2011), 1769–1818.
34. Cicero, A.F., Colletti, A., Role of phytochemicals in the management of metabolic syndrome. Phytomedicine 23:11 (2016), 1134–1144.
35. Sahebkar, A., Serban, M.C., Gluba-Brzozka, A., et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition 32:11–12 (2016), 1179–1192.
36. Johnston, T.P., Korolenko, T.A., Pirro, M., Sahebkar, A., Preventing cardiovascular heart disease: promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res 120 (2017), 219–225.
37. Nordestgaard, B.G., Chapman, M.J., Ray, K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:23 (2010), 2844–2853.
38. Pirro, M., Bianconi, V., Paciullo, F., Mannarino, M.R., Bagaglia, F., Sahebkar, A., Lipoprotein(a) and inflammation: a dangerous duet leading to endothelial loss of integrity. Pharmacol Res 119 (2017), 178–187.
39. Sahebkar, A., Simental-Mendia, L.E., Watts, G.F., et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med, 15(1), 2017, 22.
40. Sahebkar, A., Reiner, Z., Simental-Mendia, L.E., Ferretti, G., Cicero, A.F., Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism 65:11 (2016), 1664–1678.
41. Group, H.T.C., Landray, M.J., Haynes, R., et al. Effects of extended-release niacin with laropiprant in high-risk patients. New Engl J Med 371:3 (2014), 203–212.
42. Pecin, I., Reiner, Z., Alirocumab: targeting PCSK9 to treat hypercholesterolemia. Drugs Today 51:12 (2015), 681–687.
43. Zhang, X.L., Zhu, Q.Q., Zhu, L., et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med, 13, 2015, 123.
44. Sattar, N., Preiss, D., Robinson, J.G., et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diab. Endocrinol. 4:5 (2016), 403–410.
45. Ferretti, G., Bacchetti, T., Simental-Mendia, L.E., Reiner, Z., Banach, M., Sahebkar, A., Raloxifene lowers plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized placebo-Controlled trials. Cardiovas. Drugs Therapy, 2017.
46. Kotani, K., Sahebkar, A., Serban, C., et al. Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis 242:1 (2015), 87–96.
47. Serban, M.C., Sahebkar, A., Mikhailidis, D.P., et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Sci Rep, 6, 2016, 19188.
48. Sahebkar, A., Simental-Mendia, L.E., Stefanutti, C., Pirro, M., Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res 105 (2016), 198–209.
49. Catapano, A.L., Graham, I., De Backer, G., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:39 (2016), 2999–3058.
50. Aguiar, C., Alegria, E., Bonadonna, R.C., et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl 19 (2015), 1–12.
51. Reiner, Z., Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metabol. Cardiovasc. Dis. NMCD 23:9 (2013), 799–807.
52. Rached, F.H., Chapman, M.J., Kontush, A., HDL particle subpopulations: focus on biological function. BioFactors 41:2 (2015), 67–77.